Using a small extract of our much larger database (only institutional investors whose names begin with the letter “A”) and created using our proprietary Artificial Intelligence / Natural Intelligence technology for Qualifying Investment or AnNie Qi ™ by Collabrity, this site demonstrates the powerful tools Collabrity brings to supporting early-stage therapeutic biotechnology company CEOs and investors.

For CEOs "Click the "Demo" button immediately above to access the demonstration." Enter search criteria to qualify investors by up to four criteria. For example, to select investors who invest in Europe, in the first row select “GEOGRAPHY” under the Column drop-down menu and enter “Europe” in the Search Term box. To further qualify investors in Europe who have invested in cancer companies, in the second row select “DISEASE indication” under the Column drop-down menu and enter “cancer”. Regarding DISEASE indication, please note that our practice is to research each therapeutic biotech company that the investor has invested in over the past four years and capture the disease indication targeted by all pipeline assets exactly as described by the investee companies. Therefore, please consider using multiple synonyms for the disease area of interest; if, for example, finding investors in oncology companies is of interest, try "cancer", "lymphoma", "leukemia", etc..

For investors While this site provides insights into qualifying investors from the perspective of our therapeutic biotechnology company CEO clients, by maintaining another large database of therapeutic biotech companies seeking investment and structured for qualification by AnNie Qi ™ , Collabrity also delivers comparable value to investors seeking to proactively identify biotech companies meeting their investment criteria as well as to reactively qualify inbound solicitations for investment.

About Collabrity We exclusively serve therapeutic biotech companies worldwide who seek to raise less than $75 million through private placements - who we believe are underserved by their alternatives.

Please contact Collabrity CEO Chris Lehman to learn more at +1 (510) 339-3749 or chris@collabrity.com, or visit our website at https://collabrity.com